A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

Study acronym: BIFANG
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 48 → 34 locations
    • Eligibility criteria expanded, about 62 words
    • Secondary endpoints: details revised at 18 of 27 entries
  2. Trial sites expanded: 39 → 48 locationsv7
  3. Trial sites expanded: 21 → 39 locations
    • Trial sites reduced: 33 → 21 locations
    v6
  4. Study sites: 33 to 21
    • Secondary endpoints: 29 to 27
    v5
  5. Trial sites expanded: 21 → 33 locationsv4
  6. Trial sites expanded: 1 → 21 locationsv3
  7. Recruitment openedv2 Show 4 more changesShow less
    • Trial sites reduced: 51 → 1 locations
    • Study completion moved earlier from Aug 15, 2028 to Mar 7, 2028
    • Primary completion date: Mar 7, 2028 to Mar 1, 2028
    • Start date changed from estimate of May 6, 2026 to Apr 24, 2026
  8. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
Trial Details
NCT Number NCT07520162
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Chronic Rhinosinusitis With Nasal Polyps
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov